The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) closed at $19.10 in the last session, down -2.25% from day before closing price of $19.54. In other words, the price has decreased by -$2.25 from its previous closing price. On the day, 0.85 million shares were traded. RCKT stock price reached its highest trading level at $19.66 during the session, while it also had its lowest trading level at $18.74.
Ratios:
We take a closer look at RCKT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.79. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Neutral rating and assigned the stock a target price of $39.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $65.
On February 01, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $45.Morgan Stanley initiated its Overweight rating on February 01, 2023, with a $45 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 16 ’24 when Militello John sold 1,064 shares for $18.50 per share. The transaction valued at 19,688 led to the insider holds 51,451 shares of the business.
Patel Kinnari sold 3,989 shares of RCKT for $73,812 on Aug 16 ’24. The insider now owns 396,983 shares after completing the transaction at $18.50 per share. On Aug 16 ’24, another insider, Shah Gaurav, who serves as the CEO of the company, sold 9,650 shares for $18.50 each. As a result, the insider received 178,564 and left with 718,419 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCKT now has a Market Capitalization of 1737639808 and an Enterprise Value of 1484611968.
Stock Price History:
Over the past 52 weeks, RCKT has reached a high of $32.53, while it has fallen to a 52-week low of $15.27. The 50-Day Moving Average of the stock is -10.80%, while the 200-Day Moving Average is calculated to be -22.44%.
Shares Statistics:
According to the various share statistics, RCKT traded on average about 853.59K shares per day over the past 3-months and 747540 shares per day over the past 10 days. A total of 90.28M shares are outstanding, with a floating share count of 83.80M. Insiders hold about 7.88% of the company’s shares, while institutions hold 97.86% stake in the company. Shares short for RCKT as of 1722384000 were 10533156 with a Short Ratio of 12.80, compared to 1719532800 on 8407169. Therefore, it implies a Short% of Shares Outstanding of 10533156 and a Short% of Float of 24.59.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 14.0 analysts currently analyzing and rating the stock of Rocket Pharmaceuticals Inc (RCKT).The consensus estimate for the next quarter is -$0.71, with high estimates of $0.24 and low estimates of -$0.9.
Analysts are recommending an EPS of between -$1.59 and -$3.12 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$2.66, with 14.0 analysts recommending between -$1.84 and -$3.21.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $61.48M in the next fiscal year. The high estimate is $117.96M and the low estimate is $4.5M.
